GlassScriptPhysician profile
Radha Andukuri
NPI 1992921779
$3,668.12
in general payments reported to CMS, 2019-2025
37 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $206 · 2021: $174 · 2022: $219 · 2023: $592 · 2024: $1,183 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $740.10 | 2024 | |
| Novo Nordisk INC | $301.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $279.43 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Amgen INC. | $219.80 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $213.16 | 2019-2025 | Freestyle Libre 3, Eterna |
| Medtronic, INC. | $210.04 | 2022-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Abbvie INC. | $176.10 | 2019-2025 | Synthroid |
| Nestle Healthcare Nutrition INC. | $149.51 | 2023 | |
| Ascensia Diabetes Care US INC. | $127.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.23 | 2021-2025 | |
| Antares Pharma, INC. | $101.49 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.41 | 2020-2025 | |
| Horizon Therapeutics Plc | $88.61 | 2020-2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $87.37 | 2019-2021 | |
| Insulet Corporation | $85.81 | 2019-2023 | Omnipod |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $76.78 | 2019-2025 | Tymlos |
| Senseonics, Incorporated | $58.00 | 2019 | |
| Xeris Pharmaceuticals, INC. | $57.02 | 2021-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.32 | 2019 | |
| Amneal Pharmaceuticals LLC | $42.52 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $38.28 | 2019-2020 | |
| Mannkind Corporation | $34.95 | 2019-2020 | |
| Dexcom, INC. | $33.26 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $31.03 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $26.48 | 2019 | |
| Medtronic Minimed, INC. | $25.80 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $22.20 | 2022 | |
| Halozyme INC | $21.92 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $20.02 | 2019 | |
| Averitas Pharma INC. | $18.93 | 2024 | Qutenza |
| Valeritas, INC. | $18.35 | 2019 | |
| Kyowa Kirin, INC. | $17.01 | 2025 | |
| Cequr Corporation | $16.62 | 2022 | |
| Ascendis Pharma Endocrinology INC | $16.13 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $15.49 | 2025 | Twiist |
| Ibsa Pharma INC. | $14.62 | 2019 | |
| Shire North American Group INC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Andukuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.